asa guidelines for glp-1 agonists Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: a restrictive fasting regimen is not necessary. Comment on Br J Anaesth 2025; 135: 48–78 Tirzepatide for Obstructive Sleep Apnea:
Description
Both preclinical and clinical studies have consistently demonstrated significant body weight reduction (significant loss of 240320 calories/daily resulting in average weight loss of 24 kg during the first 24 weeks) after their administration
However, even though Novo has the first-mover advantage and market dominance, Eli Lillys drugs offer superior weight loss (Eli Lilly: ~20% vs
doi: 10.17219/acem/171300
GLP-1 drugs include: While GLP-1 drugs are primarily prescribed for managing diabetes, they have become increasingly popular for their effectiveness in supporting weight loss
Oxidative stress in Parkinson's disease
